Skip to main content
Access Resources

MJFF Publications

The Michael J. Fox Foundation continually strives to communicate our scientific progress with the research community — through posters and presentations at meetings, in peer-reviewed scientific publications and with white paper reports.

From
To
  • Default content image

    Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents

    Parkinson’s disease (PD) is the second most common neurodegenerative disease, affecting approximately one-percent of the population over the age of sixty. Although many animal models have been…

  • Default content image

    The Michael J. Fox Foundation’s Strategy to Generate, Characterize, and Distribute Preclinical Antibody Tools for Investigating Parkin/PINK1 and LRRK2- and PINK1-Related Rab Molecular Biology

    A field-wide challenge in Parkinson’s disease (PD) research is a general lack of availability for high-quality, reproducible, and readily accessible preclinical research tools. To address these…

  • Default content image

    The Michael J. Fox Foundation’s Efforts to Generate, Characterize, and Promote the Use of a Variety of Preclinical Models of Parkinson’s Disease

    Preclinical models are a necessary tool for investigating the pathogenesis and potential therapeutic strategies for diseases like Parkinson’s disease (PD). As the precise etiology of PD is currently…

  • Default content image

    User's guide for alpha-synuclein biomarker studies in biological fluids: Perianalytical considerations

    This article summarizes perianalytical considerations for biomarker studies (based on immunoassays) in Parkinson's disease, with emphasis on quantifying total α-synuclein protein in biological fluids…

  • Default content image

    The Michael J. Fox Foundation’s Strategy to Generate, Characterize, and Distribute Preclinical Alpha-Synuclein Research Tools for Molecular Biology

    Mutations in the gene SNCA that encodes the protein alpha-synuclein as well as postmortem pathological studies strongly implicate a general role for alpha-synuclein in Parkinson’s disease (PD)…

  • Default content image

    Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors

    Genta Ito, Kristina Katsemonova, Francesca Tonelli, Pawel Lis, Marco Baptista, Natalia Shpiro, Graham Duddy, Steve Wilson, Wing-Lok Ho, Shu-Leong Ho, Alastair D Reith, Dario R Alessi Autosomal…

  • Default content image

    Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases

    Martin Steger, Francesca Tonelli, Genta Ito, Paul Davies, Matthias Trost, Melanie Vetter, Stefanie Wachter, Esben Lorentzen, Graham Duddy, Stephen Wilson, Marco AS Baptista, Brian K Fiske, Matthew J…

Articles authored by Rachel Dolhun, MD, a movement disorder specialist on staff at MJFF, offer a practical review of topics related to Parkinson's disease for practicing clinicians.

From
To

No results were found.

Michael J. Fox Foundation publications supported through our OAP program.

We believe that the results of all MJFF-funded research should be promptly published and broadly disseminated to accelerate innovation and foster collaboration toward our shared goal of new treatments and cures for Parkinson’s disease. 

Request open access coverage funds for your MJFF project here

From
To
  • Default content image

    Allosteric Inhibition of Parkinson's-Linked LRRK2 by Constrained Peptides

    Leucine-Rich Repeat Kinase 2 (LRRK2) is a large, multidomain protein with dual kinase and GTPase function that is commonly mutated in both familial and idiopathic Parkinson's Disease (PD). While…

  • Default content image

    A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model

    The use of wildtype recombinant alpha-synuclein preformed fibrils (aSyn PFFs) to induce endogenous alpha-synuclein to form pathological phosphorylation and trigger neurodegeneration is a popular…

  • Default content image

    Miro1 Impairment in a Parkinson’s At-Risk Cohort.

    There is a lack of reliable molecular markers for Parkinson's disease (PD) patients and at-risk individuals. The detection of the pre-symptomatic population of PD will empower more effective clinical…

  • Default content image

    Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression

    Parkinson's disease (PD) diagnosis relies primarily on clinical evaluation due to lack of validated tests and biomarkers. DaTscan imaging has been used to distinguish psychogenic and drug-induced…

  • Default content image

    Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation

    LRRK2 is a highly phosphorylated multidomain protein and mutations in the gene encoding LRRK2 are a major genetic determinant of Parkinson's disease (PD). Dephosphorylation at LRRK2's S910/S935/S955…

  • Default content image

    Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor

    Neuropathological staging studies have suggested that tau pathology spreads through the brain in Alzheimer's disease (AD) and other tauopathies, but it is unclear how neuroanatomical connections,…

  • Default content image

    Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model

    Multiple mutations have been described in the human GBA1 gene, which encodes the lysosomal enzyme beta-glucocerebrosidase (GCase) that degrades glucosylceramide and is pivotal in glycosphingolipid…

Female researcher pipetting in lab.

Breaking Research Updates

Read the latest developments in the field’s understanding and treatment of Parkinson’s disease.

Read Research News
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.